As the biopharmaceutical industry experiences robust growth, companies continue to seek new ways to accelerate time to market, ensure product quality, increase flexibility in manufacturing, and reduce costs. Intensification of upstream processes offers the potential to achieve gains in all these areas.
The upstream manufacturing workflow typically starts with a cryopreserved vial taken from a working cell bank created from a master cell bank. The vial is thawed, and cells are expanded until sufficient biomass is reached to inoculate the final end stage bioreactor run in either fed batch or perfusion mode.
Several opportunities exist to optimize this stage of manufacturing. Learn about two novel strategies to intensify seed train operations using high cell density cryopreservation (HCDC) and a medium designed for seed train expansion and N-1 perfusion applications. These approaches shorten the seed train workflow, improve reproducibility, and reduce the risk of contamination. Flexibility is also increased as the upstream process can begin with sufficient cells from cryopreservation, eliminating multiple expansion steps and allowing direct inoculation of the first seed train bioreactor.